CompanyGraphAt a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $7.61M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 6.26: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.12BUSDvs all stocks (USD)
Revenue (TTM)
7.61MUSDvs all stocks (USD)
Beta
1.74xvs all stocks
52-Week Change
26.19%vs all stocks
Market Capitalization
1.12BUSDvs all stocks (USD)
Enterprise Value
1.24BUSDvs all stocks (USD)
Forward P/E
-4.49xvs Biotechnology peers
Price to Book (MRQ)
33.59xvs Biotechnology peers
Enterprise to Revenue
162.22xvs Biotechnology peers
Enterprise to EBITDA
-4.42xvs Biotechnology peers
Gross Margin
24.14%vs Biotechnology peers
Operating Margin
-450.65%vs Biotechnology peers
Return on Assets (TTM)
-54.13%vs Biotechnology peers
Return on Equity (TTM)
-102.71%vs Biotechnology peers
Revenue (TTM)
7.61MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0980USDUpdated Jul 18, 2026Quarterly Revenue Growth
161.70%vs Biotechnology peers
Gross Profit (TTM)
-224.75MUSDvs all stocks (USD)
EBITDA (TTM)
-279.38MUSDvs all stocks (USD)
Net Income (TTM)
-271.60MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-97.15%vs Biotechnology peers
Operating Cash Flow (TTM)
-267.54MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-168.72MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
31.37MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
2.07MUSDFY2025 · Dec 31, 2025Gross Profit
29.30MUSDFY2025 · Dec 31, 2025Operating Income
-243.43MUSDvs all stocks (USD)
Pre-tax Income
-231.68MUSDFY2025 · Dec 31, 2025Income Tax Expense
279.00KUSDFY2025 · Dec 31, 2025Net Income
-231.96MUSDFY2025 · Dec 31, 2025EBIT
-231.65MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-229.34MUSDFY2025 · Dec 31, 2025Research & Development
221.04MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
51.70MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
11.78MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
33.00KUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.17USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.17USDFY2025 · Dec 31, 2025Basic Shares Outstanding
73.25MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
73.25MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-231.96MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-244.79MUSDFY2025 · Dec 31, 2025Free Cash Flow
-247.91MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
101.97MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-231.96MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.31MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
279.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
27.87MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-4.83MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-10.67MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-27.79MUSDFY2025 · Dec 31, 2025Capital Expenditures
-3.13MUSDFY2025 · Dec 31, 2025Purchase of Investments
-252.02MUSDFY2025 · Dec 31, 2025Sale of Investments
323.73MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
68.58MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-105.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.93MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
171.41MUSDFY2025 · Dec 31, 2025Shares Outstanding
83.45MSharesUpdated Jul 18, 2026Float Shares
70.47MSharesUpdated Jul 18, 2026Shares Short
15.11MSharesUpdated Jul 18, 2026Short Ratio
11.30daysvs all stocks
Short % of Shares Outstanding
19.00%vs all stocks
% Held by Insiders
3.68%vs all stocks
% Held by Institutions
111.79%vs all stocks
Total Cash (MRQ)
45.26MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.4770USDUpdated Jul 18, 2026Total Debt (MRQ)
17.62MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.4682xvs Biotechnology peers
Current Ratio (MRQ)
6.66xvs Biotechnology peers
Book Value per Share (MRQ)
0.3960USDUpdated Jul 18, 2026Total Assets
364.00MUSDvs all stocks (USD)
Total Current Assets
328.65MUSDFY2025 · Dec 31, 2025Total Liabilities
57.88MUSDFY2025 · Dec 31, 2025Total Non-current Assets
35.34MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
20.86MUSDFY2025 · Dec 31, 2025Total Current Liabilities
37.02MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
101.82MUSDFY2025 · Dec 31, 2025Other Short-term Investments
204.26MUSDFY2025 · Dec 31, 2025Accounts Receivable
651.00KUSDFY2025 · Dec 31, 2025Inventory
1.81MUSDFY2025 · Dec 31, 2025Accounts Payable
10.49MUSDFY2025 · Dec 31, 2025Deferred Revenue
0.00USDFY2025 · Dec 31, 2025Other Current Liabilities
2.14MUSDFY2025 · Dec 31, 2025Long-term Debt
20.77MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
87.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
83.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.10BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
306.11MUSDvs all stocks (USD)
52-Week Low
9.40USDUpdated Jul 18, 202652-Week High
19.11USDUpdated Jul 18, 202652-Week Change
26.19%vs all stocks
Beta
1.74xvs all stocks
50-Day MA
13.26USDUpdated Jul 18, 2026200-Day MA
14.15USDUpdated Jul 18, 2026Avg 10-Day Volume
1.53MSharesUpdated Jul 18, 2026Avg 30-Day Volume
1.46MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-3.51USDUpdated Jul 18, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 6.26: safe zoneNotable
Altman Z-Score: 6.26
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $7.61M, lower than 95% of all stocks globallySignificant
Revenue (USD): 7,614,000Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
China Resources Boya Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangxi Wuzhou Zhongheng Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Frontier Biotechnologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shinva Medical Instrument Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Oric Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Wave Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sichuan Huiyu Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inventiva S.A.
Tier 1ProductionApproval-Gated PipelineRule
Inkon Life Tech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Capricor Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
A2Z Cust2Mate Solutions Corp
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Beam Therapeutics Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Wave Life Sciences Ltd.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC